Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin + Pembrolizumab vs Doxorubicin Alone in DDLPS, UPS and Related Sarcomas
NCT06422806Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Apr 2032
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in dedifferentiated liposarcoma (DDL), undifferentiated pleomorphic sarcoma (UPS) and soft tissue sarcoma (STS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 5 years. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
dedifferentiated liposarcoma (DDL)undifferentiated pleomorphic sarcoma (UPS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06422806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422806.